Novel fibroblast growth factor receptor modulator for treating neurodegenerative diseases

5-HT2 antagonist

Potent Inhibitor of Plasmodium FK506 Binding Protein 35 (FKBD35), also act as a HIV inhibitor

Antagonist of the mammalian bile acid sensor farnesoid-X-receptor (FXR)

Selective D2 dopamine receptor antagonist

D2 dopamine receptor partial agonist in adenylyl cyclase inhibition assay and antagonist in the GIRK and phospho ERK1/2 assays

Novel clickable tumor-specific irreversible inhibitor of stearoyl CoA desaturase (SCD)

Natural potent alpha-mannosidase inhibitor, exhibiting antimetastatic, antiproliferative, and immunomodulatory activities

Potent differentiating agent

Novel selective OXE receptor antagonist

Novel highly potent and selective CDK7 inhibitor, demonstrating broad anti-tumor activity in vivo

Novel universal opioid receptor agonist

Novel inhibitor of the Syk kinase (spleen tyrosine kinase)

Novel potent and specific inhibitor of syncytin-mediated cell fusion, completely blocking cell fusion at 1.6 μg/ml

Negative control of Syn-1 peptide, having the same amino acid composition as Syn-1 peptide, but a scrambled sequence

Novel Mycobacterium tuberculosis growth inhibitor

Novel microtubule-stablizer

K+ channel blocker

Novel TLR7 agonist via immune response induction and tumor microenvironment modulation

Potent inhibitor of both rodent and human MAO-B, proved to be safe in high doses with no hERG and mutagenic activities and demonstrated neuroprotection in an in vivo chronic model of PD

Novel COX-2 inhibitor

Potent and selective CCKA receptor antagonist